表紙
市場調査レポート

ETS6103 (大うつ病性障害)-予測と市場分析

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 305490
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
ETS6103 (大うつ病性障害)-予測と市場分析 ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023
出版日: 2014年05月30日 ページ情報: 英文 59 Pages
概要

大うつ病性障害(MDD)は世界で最も一般的な精神疾患の一つであり、その治療薬市場は競合が激しく、30を超える製品が上市されています。Eli Lillyの Cymbalta,大塚製薬/BMSのAbilifyといった主要製品の特許切れや、Lundbeck/武田医薬品のBrintellixなど最終段階のパイプライン製品の投入を目前に、市場は大きく動いています。ETS6103はSSRIによる初期治療の効果が十分にでないMDD患者に対する治療薬としてe-Therapeutics によって開発が進められています。ETS6103は中等度〜重度の疼痛に対する鎮痛剤として指定されているトラマドールの放出制御製剤です。

当レポートでは、大うつ病性障害の治療薬であるETS6103について調査分析し、疾病の概要と治療ガイドライン、競合情勢、製品情報、売上予測などをまとめ、お届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 分類
  • 症状およびサブタイプ
  • 予後
  • QOL

第4章 疾病の管理

  • 症状と治療の概要

第5章 競合評価

  • 概要

第6章 機会とアンメットニーズ

  • 概要
  • より効果的な薬物療法
  • より良好な副作用プロファイル
  • 抗うつ効果の迅速な発現
  • 個別化医療のアプローチ

第7章 パイプライン分析

  • 概要
  • 臨床開発中の有望な薬剤

第8章 ETS6103

  • 概要
  • 効能
  • 安全性
  • 投与と処方
  • 臨床および市場における潜在的な位置づけ
  • SWOT分析
  • 予測

第9章 付録

図表

目次
Product Code: GDHC431DFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

ETS6103 is being developed by e-Therapeutics for the treatment of MDD in patients who have not responded adequately to first-line therapy with an SSRI. ETS6103 is a controlled-release formulation of tramadol (e-Therapeutics, press release, October 31, 2013). Tramadol is a centrally acting synthetic analgesic compound, which is indicated for the treatment of moderate-to-severe pain.

Scope

  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on ETS6103 including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for ETS6103 for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of ETS6103 performance
  • Obtain sales forecast for ETS6103 from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2. Introduction

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Related Reports

3. Disease Overview

  • 3.1 Etiology and Pathophysiology
    • 3.1.1 Etiology
    • 3.1.2 Pathophysiology
  • 3.2 Classification
  • 3.3 Symptoms and Subtypes of Major Depressive Disorder
  • 3.4 Prognosis
  • 3.5 Quality of Life

4. Disease Management

  • 4.1 Diagnosis and Treatment Overview
    • 4.1.1 Diagnosis
    • 4.1.2 Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3 Clinical Practice

5. Competitive Assessment

  • 5.1 Overview

6. Unmet Needs and Opportunities

  • 6.1 Overview
  • 6.2 More Effective Pharmacotherapies
    • 6.2.1 Unmet Needs
    • 6.2.2 Gap Analysis
    • 6.2.3 Opportunities
  • 6.3 More Favorable Side Effect Profiles
    • 6.3.1 Unmet Needs
    • 6.3.2 Gap Analysis
    • 6.3.3 Opportunities
  • 6.4 Rapid Onset of Antidepressant Effects
    • 6.4.1 Unmet Needs
    • 6.4.2 Gap Analysis
    • 6.4.3 Opportunities
  • 6.5 Personalized Treatment Approach
    • 6.5.1 Unmet Needs
    • 6.5.2 Gap Analysis
    • 6.5.3 Opportunities

7. Pipeline Assessment

  • 7.1 Overview
  • 7.2 Promising Drugs in Clinical Development

8. ETS6103

  • 8.1 Overview
  • 8.2 Efficacy
  • 8.3 Safety
  • 8.4 Dosing and Formulation
  • 8.5 Potential Clinical and Commercial Positioning
  • 8.6 SWOT Analysis
  • 8.7 Forecast

9. Appendix

  • 9.1 Bibliography
  • 9.2 Abbreviations
  • 9.3 Methodology
  • 9.4 Forecasting Methodology
    • 9.4.1 Diagnosed MDD Patients
    • 9.4.2 Percent of Drug-Treated Patients
    • 9.4.3 General Pricing Assumptions
    • 9.4.4 Generic Erosion
    • 9.4.5 Pricing of Pipeline Agents
  • 9.5 Physicians and Specialists Included in this Study
  • 9.6 About the Authors
    • 9.6.1 Analyst
    • 9.6.2 Therapy Area Directors
    • 9.6.3 Global Head of Healthcare
  • 9.7 About GlobalData
  • 9.8 Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)
  • Table 2: Subtypes of Major Depressive Disorder
  • Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria
  • Table 4: Treatment Guidelines for Major Depressive Disorder
  • Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013
  • Table 6: Leading Treatments for MDD, 2013
  • Table 7: Unmet Needs and Opportunities in MDD
  • Table 8: Comparison of Therapeutic Classes in Development for MDD, 2013
  • Table 9: Product Profile - ETS6103
  • Table 10: ETS6103 SWOT Analysis, 2014
  • Table 11: Global MDD Sales Forecasts ($m) for ETS6103, 2013-2023
  • Table 12: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
  • Figure 2: Disease Management Model for Major Depressive Disorder
  • Figure 3: Major Depressive Disorder Treatment Algorithm
  • Figure 4: MDD - Phase IIb-III Pipeline, 2014
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2013-2023
  • Figure 6: Clinical and Commercial Positioning of ETS6103
Back to Top